---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-091222"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:41:22.718845+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eloxx Q2 net loss $10.6M; cash $30M; CF topline data expected Q3 2022

## Summary
- Q2 2022 net loss $10.6M ($0.12/sh) vs $36.1M ($0.54/sh) in Q2 2021; prior year included $22.7M Zikani acquisition expense.
- Cash and equivalents $30.0M as of June 30, 2022; sufficient to fund operations into Q4 2023; in compliance with debt covenants.
- CF Phase 2 expansion arms top-line results expected by end of Q3 2022; inhaled delivery IND on track for Q4 2022.
- Alport syndrome proof-of-concept trial to start H2 2022 in up to 8 patients; topline results expected H1 2023.
- ZKN-013 repeat study confirms potential in FAP model; IND for FAP expected H2 2023; RDEB IND on track for Q4 2022.

## SEC filing metadata
- accession: 0001104659-22-091222
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465922091222/0001104659-22-091222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465922091222/tm2223461d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-091222
- JSON: https://secwatch.observer/filing/0001104659-22-091222.json
- Plain text: https://secwatch.observer/filing/0001104659-22-091222.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.